Identification of MTCH1 as a novel prognostic indicator and therapeutic target in hepatocellular carcinoma
Pathology - Research and Practice · 2024
DOI: 10.1016/j.prp.2024.155358 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology - Research and Practice, 2024. Verfasst von Liangpeng Xie und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of hematology, the Third Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Hunan Provincial Natural Science Foundation.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) emerges as the third leading cause of cancer mortality, contributing to approximately 830,000 deaths annually. The mechanisms driving its pathogenesis remain largely elusive. Through bioinformatic scrutiny, Mitochondrial Carrier 1 (MTCH1), a component of the mitochondrial carrier family, has been pinpointed as potentially pivotal in HCC evolution. Examination of The Cancer Genome Atlas (TCGA) database indicated a pronounced increase in MTCH1 expression within HCC tissues versus normal liver counterparts. Subsequent analyses, utilizing both Kaplan-Meier mapper and Gene Expression Profiling Interactive Analysis (GEPIA) datasets, associated elevated MTCH1 levels with reduced overall survival (OS) and disease-free survival (DFS). Complementary in vitro assessments confirmed that MTCH1 downregulation suppresses HCC cell proliferation and notably diminishes HCC xenograft tumor growth in murine models. Additional explorations, including Gene Set Enrichment Analysis (GSEA), STRING database interrogation, and quantitative PCR (qPCR) experiments, suggest MTCH1's involvement in HCC progression via the CDK-RB-E2F signaling axis. Collectively, these insights endorse MTCH1 as a promising therapeutic target for HCC, underscoring its significance in the disease's molecular framework and potential treatment innovation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of hematology, the Third Xiangya Hospital, Central South University, Changsha, China.
- Department of Gastroenterology, the Third Xiangya Hospital, Central South University, Changsha, China.
- Department of Gynecology, the Third Xiangya Hospital, Central South University, Changsha, China.
- Department of Health Management Center, the Third Xiangya Hospital, Central South University, Changsha, China. Electronic address: lypei123@163.com.
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Hunan Provincial Natural Science Foundation
- Hunan Province Health Commission
Zitieren
APA
Xie, L., Shu, Y., Ye, M., & Li, Y. (2024). Identification of MTCH1 as a novel prognostic indicator and therapeutic target in hepatocellular carcinoma. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2024.155358
Vancouver
Xie L, Shu Y, Ye M, Li Y. Identification of MTCH1 as a novel prognostic indicator and therapeutic target in hepatocellular carcinoma. Pathology - Research and Practice. 2024. doi:10.1016/j.prp.2024.155358
BibTeX
@article{Xie2024,
author = {Xie, Liangpeng and Shu, Yufeng and Ye, Mingzhu and Li, Yapei},
title = {Identification of MTCH1 as a novel prognostic indicator and therapeutic target in hepatocellular carcinoma},
journal = {Pathology - Research and Practice},
year = {2024},
doi = {10.1016/j.prp.2024.155358}
}
EUVIMED